Mesothelioma, Malignant Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting mesothelioma, malignant clinical trials across 9 countries. Studies span Phase 1, Phase 2, Not Applicable. Top locations include New York, New York, United States, Seattle, Washington, United States, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Mesothelioma, Malignant Trials at a Glance

11 actively recruiting trials for mesothelioma, malignant are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in New York, Seattle, and Chicago. Lead sponsors running mesothelioma, malignant studies include A2 Biotherapeutics Inc., Cancer Research UK, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse mesothelioma, malignant trials by phase

Treatments under study

About Mesothelioma, Malignant Clinical Trials

Looking for clinical trials for Mesothelioma, Malignant? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mesothelioma, Malignant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mesothelioma, Malignant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian CancerMesothelioma, MalignantCholangiocarcinoma Recurrent
Verismo Therapeutics42 enrolled5 locationsNCT05568680
Recruiting
Phase 1

SW-682 in Advanced Solid Tumors

Advanced Solid TumorMesothelioma, Malignant
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany186 enrolled8 locationsNCT06251310
Recruiting
Not Applicable

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

MesotheliomaMesothelioma, MalignantMesothelioma Malignant Advanced+2 more
University of Chicago30 enrolled1 locationNCT07126509
Recruiting
Phase 2

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Malignant MesotheliomaMesotheliomaMesothelioma, Malignant+2 more
Memorial Sloan Kettering Cancer Center64 enrolled13 locationsNCT06057935
Recruiting
Phase 1Phase 2

HTL0039732 in Participants With Advanced Solid Tumours

SarcomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms+11 more
Cancer Research UK150 enrolled5 locationsNCT05944237
Recruiting
Phase 2

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, MalignantMesothelioma, Malignant PleuralMesothelioma Malignant Advanced
Cancer Institute and Hospital, Chinese Academy of Medical Sciences29 enrolled2 locationsNCT05188859
Recruiting
Phase 1Phase 2

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Not Applicable

First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.

Pleural Effusion, MalignantMesothelioma, MalignantPleural Effusion+1 more
National and Kapodistrian University of Athens100 enrolled1 locationNCT06946498
Recruiting

Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS

Mesothelioma, Malignant Pleural
Fondazione IRCCS Policlinico San Matteo di Pavia60 enrolled2 locationsNCT06886672